Literature DB >> 27909065

Cdk5 Directly Targets Nuclear p21CIP1 and Promotes Cancer Cell Growth.

Pao-Hsuan Huang1, Mei-Chih Chen2, Yu-Ting Peng1, Wei-Hsiang Kao1, Chih-Hsiang Chang1, Yun-Chi Wang1, Chih-Ho Lai3, Jer-Tsong Hsieh4, Jo-Hsin Wang1, Yueh-Tsung Lee1,5, Eugene Lin1,6, Chia-Herng Yue1,7, Hsin-Yi Wang1,8, Shuen-Chi You1, Ho Lin9,10,11,12,13.   

Abstract

The significance of Cdk5 in cell-cycle control and cancer biology has gained increased attention. Here we report the inverse correlation between the protein levels of Cdk5 and p21CIP1 from cell-based and clinical analysis. Mechanistically, we identify that Cdk5 overexpression triggers the proteasome-dependent degradation of p21CIP1 through a S130 phosphorylation in a Cdk2-independent manner. Besides, the evidence from cell-based and clinical analysis shows that Cdk5 primarily regulates nuclear p21CIP1 protein degradation. S130A-p21CIP1 mutant enables to block either its protein degradation or the increase of cancer cell growth caused by Cdk5. Notably, Cdk5-triggered p21CIP1 targeting primarily appears in S-phase, while Cdk5 overexpression increases the activation of Cdk2 and its interaction with DNA polymerase δ. The in vivo results show that Cdk2 might play an important role in the downstream signaling to Cdk5. In summary, these findings suggest that Cdk5 in a high expression status promotes cancer growth by directly and rapidly releasing p21CIP1-dependent cell-cycle inhibition and subsequent Cdk2 activation, which illustrates an oncogenic role of Cdk5 potentially applied for future diagnosis and therapy. Cancer Res; 76(23); 6888-900. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27909065     DOI: 10.1158/0008-5472.CAN-15-3253

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.

Authors:  Caroline M Robb; Smit Kour; Jacob I Contreras; Ekta Agarwal; Carter J Barger; Sandeep Rana; Yogesh Sonawane; Beth K Neilsen; Margaret Taylor; Smitha Kizhake; Rhishikesh N Thakare; Sanjib Chowdhury; Jing Wang; Jennifer D Black; Michael A Hollingsworth; Michael G Brattain; Amarnath Natarajan
Journal:  Oncotarget       Date:  2017-12-28

2.  The Cyclin-Dependent Kinase 5 Inhibitor Peptide Inhibits Herpes Simplex Virus Type 1 Replication.

Authors:  Adrian Man; Mark Slevin; Eugen Petcu; Cornel Fraefel
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

Review 3.  Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications.

Authors:  Muhammet Oner; Eugene Lin; Mei-Chih Chen; Fu-Ning Hsu; G M Shazzad Hossain Prince; Kun-Yuan Chiu; Chieh-Lin Jerry Teng; Tsung-Ying Yang; Hsin-Yi Wang; Chia-Herng Yue; Ching-Han Yu; Chih-Ho Lai; Jer-Tsong Hsieh; Ho Lin
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

4.  RAGE acts as an oncogenic role and promotes the metastasis of human lung cancer.

Authors:  Mei-Chih Chen; Kun-Chieh Chen; Gee-Chen Chang; Ho Lin; Chun-Chi Wu; Wei-Hsiang Kao; Chieh-Lin Jerry Teng; Shih-Lan Hsu; Tsung-Ying Yang
Journal:  Cell Death Dis       Date:  2020-04-23       Impact factor: 8.469

5.  A kinase of many talents: non-neuronal functions of CDK5 in development and disease.

Authors:  Samanta Sharma; Piotr Sicinski
Journal:  Open Biol       Date:  2020-01-08       Impact factor: 6.411

Review 6.  Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment.

Authors:  Oana-Maria Thoma; Markus F Neurath; Maximilian J Waldner
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

Review 7.  Post-translational modifications of CDK5 and their biological roles in cancer.

Authors:  Gui-Bin Gao; Yue Sun; Run-Dong Fang; Ying Wang; Yang Wang; Qing-Yu He
Journal:  Mol Biomed       Date:  2021-07-20

8.  Cdk5 regulates IP3R1-mediated Ca2+ dynamics and Ca2+-mediated cell proliferation.

Authors:  Saranya NavaneethaKrishnan; Vincent Law; Jungkwon Lee; Jesusa L Rosales; Ki-Young Lee
Journal:  Cell Mol Life Sci       Date:  2022-08-24       Impact factor: 9.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.